Tryptase and Coronary Heart Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of this study will evaluate differences in serum levels of tryptase in study population. Will be selected a number of 350 patients hospitalized for coronary heart disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Tryptase Levels in Patients With Stable Coronary Artery Disease.

NCT06958016

Chronic Coronary Syndrome

RECRUITING

Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome

NCT01698021

Acute Coronary Syndrome Myocardial Infarction Unstable Angina

UNKNOWN

Biomarkers in Patients Hospitalized With Suspected Acute Myocardial Infarction

NCT04167904

Myocardial Infarction, Acute

COMPLETED

Induced Myocardial Ischemia: a Serial Troponin T and Troponin I Measurements

NCT03203057

Acute Coronary Syndrome Cardiac Ischemia

COMPLETED

Novel Biomarkers in Patients With Acute Myocardial Infarction

NCT05791916

Cardiovascular Diseases Myocardial Infarction Acute Coronary Syndrome +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A series of scientific studies have evaluated the tryptase as a biomarker of coronary plaque instability, in the course of ischemic heart disease. Among these, the most recent and 'outcome' is better defined by Meixiang Xiang study, which has been conducted in 2011 on 270 patients. This study evaluated and compared the levels of tryptase in four populations:

1. acute myocardial infarction (31 subjects)
2. unstable angina (108 subjects)
3. stable angina (36 subjects)
4. coronary artery disease with coronary stenosis \<50% (95 subjects). In this Chinese population the final evaluations have led to define the tryptase as a marker independent of instability of the atheromatous plaque.

In reference to the fact that there is still some correlation between tryptase and coronary plaque instability and clinical symptoms, we propose a verification study of the role of tryptase as a biomarker in acute coronary conditions by studying a large population of Italian subjects in the acute phase of pathology and follow up.

The work will be conducted on 4 patient population:

1. acute coronary syndrome with ST elevation on electrocardiogram;
2. acute coronary syndrome without ST elevation on electrocardiogram (acute myocardial infarction with ST-segment depression on electrocardiogram and unstable angina)
3. noncritical coronary artery disease with coronary stenosis \<50%;
4. aortic aneurysms. Secondary endpoints will evaluate the role of tryptase in the event of major cardiovascular events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome With ST Elevation on Electrocardiogram Acute Coronary Syndrome Without ST Elevation on Electrocardiogram Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent Aortic Aneurysms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tryptase

Patients with clinical manifestations have been discovered and documented symptoms of coronary heart

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male and female subjects aged 18 to 80 years
* patients with clinical manifestations have been discovered and documented symptoms of coronary heart disease
* all patients with these characteristics will necessarily have to sign the informed consent for inclusion in the study

Exclusion Criteria

* patients with allergy symptoms in place (hives, uncontrolled asthma) autoimmune diseases, mastocytosis, hypereosinophilia, myelodysplastic syndrome, cancer, kidney failure
* those who deny consent to participate

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No